Insider Cluster (4 insiders) ·Filed Jul 7, 2026

CYTK

CYTOKINETICS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago
Insider cluster: 3 insiders, $2.3M total
Actionable Insight • Neutral

The insider selling is routine and immaterial in size. Monitor for any upcoming clinical or regulatory catalysts (CYTK is a biotech) that could drive the stock, but this cluster provides no actionable edge.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
CYTK ▼ -22.97% at T+60d
NEUTRAL call ✗ call lost -22.97% · α vs SPY -24.96% · entry $85.56 → $65.91
Entry anchored
Jul 6, 03:59 PM ET
via exchange tick
T+1d
-0.79%
call -0.79% · α -0.49%
$84.88
settled 3mo ago
T+5d
-4.24%
call -4.24% · α -4.79%
$81.93
settled 3mo ago
T+20d
-10.65%
call -10.65% · α -11.98%
$76.45
settled 2mo ago
T+60d
-22.97%
call -22.97% · α -24.96%
$65.91
settled 3d ago

Price Chart

Loading chart...

Executive Summary

Four CYTK insiders (CEO, CFO, CCO, EVP R&D) sold a total of $2.32M in shares over a one-week window, but this represents only ~0.02% of the company's $10.6B market cap. The sales are trivial in proportion to company size and include a routine cashless exercise by the EVP R&D. No material signal for the stock.

Key Financial Metrics

Direction
selling
Total Value
$2.3M
Insiders
4

Key Facts

  • Total insider sales of $2.32M over 7 days (4 transactions)
  • Sales represent ~0.02% of CYTK's $10.6B market cap
  • CEO Robert Blum sold $637K, CCO Andrew Callos sold $1.29M, CFO Sung Lee sold $98K, EVP R&D Fady Malik sold $303K (including derivative exercise)
  • All sales are open-market or cashless exercises; no pattern suggests material non-public information

Financial Impact

Insider sales of $2.32M, negligible relative to $10.6B market cap

insider ownership

Risk Factors

  • Insider sales could increase if the stock continues to appreciate, but current levels are trivial

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (28 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CYTK-1783490503419
32 reports for CYTK
Performance horizon
89% Hit rate 8 of 9 directional calls best @ T+20▲ +10.38%Mar 31, 2026
Filters
Rows
Reports for CYTK — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
BEARISH ★ 5/10
$69.31 $67.59▲ +2.48%▲ +4.59%$65.60 (+5.35%)
Sep 11, 2026
20d ago
Insider Cluster
NEUTRAL ★ 2/10
$72.45 $67.56▼ −6.75%▼ −6.86%$65.60 (−9.45%)
Sep 1, 2026
4w ago
Insider Cluster
NEUTRAL ★ 2/10
$71.40 $74.11▲ +3.80%▲ +3.71%$65.60 (−8.12%)
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$71.40 $74.11▲ +3.80%▲ +3.71%$65.60 (−8.12%)
Aug 29, 2026
4w ago
Press Release
BULLISH ★ 7/10
$70.91 $75.35▲ +6.26%▲ +6.40%$65.60 (−7.49%)
Aug 28, 2026
5w ago
8-K
BULLISH ★ 7/10
$72.09 $72.72▲ +0.87%▲ +0.76%$65.60 (−9.00%)
Jul 30, 2026
9w ago
Insider Cluster
NEUTRAL ★ 2/10
$80.42 $81.37▲ +1.18%▼ −2.44%$65.60 (−18.43%)
Jul 27, 2026
9w ago
Insider Cluster
NEUTRAL ★ 2/10
$80.62 $77.13▼ −4.33%▼ −5.40%$65.60 (−18.63%)
Jul 23, 2026
10w ago
Press Release
NEUTRAL ★ 2/10
$80.74 $80.42▼ −0.40%▼ −0.77%$65.60 (−18.75%)
Jul 14, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$81.93 $79.11▼ −3.44%▼ −2.15%$65.60 (−19.93%)
Showing 10 of 32

US Market Status

Market Closed — Opens Mon (65h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 8, 2026